Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
TMO
FY2026 Q1
Повышен
Отчётный звонок Thermo Fisher Scientific Inc
Вывод Buzzberg
Company raises full-year revenue and EPS guidance.
Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%).
Вывод Buzzberg Company raises full-year revenue and EPS guidance. Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%). Читать полный анализСвернуть анализ
Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%).
- Full-year revenue guidance raised to $47.3-$48.1B, EPS to $24.64-$25.12.
- Biopharma end market led growth; academic/government and diagnostics were soft.
- Completed Clario acquisition ($9B) and highlighted NVIDIA and OpenAI collaborations.
Выручка$11.005B-10% к/к
EPS$5.44-17% к/к
Валовая маржа40.67%Факт
Операционная маржа16.93%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
M&A
Clario acquisition completed, contributing to guidance.
Demand
Clinical research business delivering strong growth and share gains.
Показать ещё 3 тезиса
AI
AI collaboration with NVIDIA progressing toward commercialization.
Margins
Tariffs and related FX impact Q1 margins by 80 bps.
Macro
Higher inflation placeholder in guidance for future quarters.
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $11.005B | -10% к/к |
| EPS | $5.44 | -17% к/к |
| Валовая маржа | 40.67% | Факт |
| Операционная маржа | 16.93% | Факт |
| Свободный денежный поток | $0.816B | Факт |
| Капзатраты | $0.376B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Капзатраты | FY2026 | $1.9B–$2.1B | $2B | Обозначен |
| EPS | FY2026 | $24.64–$25.12 | $24.88 | Повышен |
| EPS | FY2026 Q2 | $5.69–$5.74 | $5.71 | Обозначен |
| Свободный денежный поток | FY2026 | $6.9B–$7.4B | $7.15B | Обозначен |
| Выручка | FY2026 | $47.3B–$48.1B | $47.7B | Повышен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed confidence in meeting guidance and highlighted strong execution, innovation, and strategic acquisitions as drivers of future growth.
Оценка AI от менеджмента
Management discussed AI adoption as a positive tailwind, citing collaborations with NVIDIA and OpenAI, and believes AI will accelerate scientific discovery and enhance their competitive advantage. They are embedding AI across instruments and clinical research to improve customer outcomes.
все упомянутые компании ниже: 2
Компаниис момента звонка
Партнёры
Партнёры
Mark Casper
Thermo Fisher is integrating NVIDIA's AI into lab instruments to create commercial workflow solutions, potentially boosting NVIDIA's presence in life sciences.
Доказательства
“We announced a strategic collaboration with NVIDIA, combining our leadership and laboratory technologies with Navidius advanced AI capabilities.”
OPENAI
Партнёры
Mark Casper
Thermo Fisher's earlier collaboration with OpenAI is supporting clinical research AI tools, though no new specifics were provided.
Доказательства
“we had announced some time ago with open Ai and you know customers value that and that position is very well”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 2. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.